Inventiva S.A. IVA
Annual
Quarterly
No annual revenue total was found in Inventiva S.A.'s SEC filings.
Inventiva S.A. (IVA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-49.63M
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
193.24M
+102.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IVA (Nasdaq), IVEVF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Daix, France
- SEC filer status
- Accelerated filer
- SEC CIK
- 1756594
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2021 Dec 31, 2021 |
|---|---|
| Net income | -$49.6M |
| Total assets | $122.0M |
| Stockholders' equity | $88.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 6, 2026 | Oct 6, 2026 |
| 6-K | Current report (foreign issuer) | Sep 28, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 3, 2026 | Sep 2, 2026 |
| 6-K | Current report (foreign issuer) | Sep 1, 2026 | Aug 31, 2026 |
| 6-K/A | Form 6-k/a | Jul 30, 2026 | Jul 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 29, 2026 | Jul 29, 2026 |
All 228 Inventiva S.A. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.